Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onvansertib + nal-IRI + Leucovorin + 5-FU in Second-Line Metastatic Pancreatic Cancer
NCT04752696Phase 2Terminated
- Sponsor
- Cardiff Oncology
- Start
- May 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of onvansertib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Cardiff Oncology. Started May 2021; status: terminated.
02
Drugs
onvansertib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04752696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752696.